Abstract
Background. The Silzone technology In Latvia and Europe was first introduced in 1997 with the potential to reduce prosthetic valve endocarditis. But in January 2000 the St. Jude Silzone heart valves were recalled after a clinical trial showed valves with a silver coating were prone to specific postoperative complications- paravalvular leak and higher rate of thromboembolism.
This report details our experience with the St. Jude Medical Silzone prosthesis.
Methods. From March 1998 to January 2000, the SJM Silzone valve was implanted in 41 patient (19 aortic, 14 mitral, 8 both valves). The mean age was 51,8 years (range 20-71 years), and there were 115 women (36,6%) and 2 concomitant procedures (coronary artery bypass 4,8%). Ten of the patients were in NYHA class IV, and 31 in class III; seven patients had active endocarditis. At the time of study 23 (56,1%) of these patients were alive, 13 (31,7%) were died (different reasons) and 5 (12,2%) untraceable. In summer 2012 late follow up- interview and transthoracic echocardiography was performed in 52% of survivors.
Results. All other patients are symptom-free, without evidence of infection and perivalvular leak. Echocardiography did not demonstrate the presence of thrombus or paravalvular leakage. There were two episodes of bleeding due to overdosed oral anticoagulant and no embolic complications. All patients showed significant improvement in NYHA clases.
Conclusions. Our single center study showed freedom from any paravalvular leakage in survivors with implanted SJM Silzone valve. All SJM Silzone valves showed good hemodynamic results. Perhaps higher rate of paravalvular leak is due to native valve pathology not to prosthesis with a silver coating itself?
This report details our experience with the St. Jude Medical Silzone prosthesis.
Methods. From March 1998 to January 2000, the SJM Silzone valve was implanted in 41 patient (19 aortic, 14 mitral, 8 both valves). The mean age was 51,8 years (range 20-71 years), and there were 115 women (36,6%) and 2 concomitant procedures (coronary artery bypass 4,8%). Ten of the patients were in NYHA class IV, and 31 in class III; seven patients had active endocarditis. At the time of study 23 (56,1%) of these patients were alive, 13 (31,7%) were died (different reasons) and 5 (12,2%) untraceable. In summer 2012 late follow up- interview and transthoracic echocardiography was performed in 52% of survivors.
Results. All other patients are symptom-free, without evidence of infection and perivalvular leak. Echocardiography did not demonstrate the presence of thrombus or paravalvular leakage. There were two episodes of bleeding due to overdosed oral anticoagulant and no embolic complications. All patients showed significant improvement in NYHA clases.
Conclusions. Our single center study showed freedom from any paravalvular leakage in survivors with implanted SJM Silzone valve. All SJM Silzone valves showed good hemodynamic results. Perhaps higher rate of paravalvular leak is due to native valve pathology not to prosthesis with a silver coating itself?
| Original language | English |
|---|---|
| Pages (from-to) | 76-76 |
| Number of pages | 1 |
| Journal | Journal of Cardiovascular Surgery |
| Volume | 54 |
| Issue number | 2, Suppl.1 |
| Publication status | Published - 2013 |
| Externally published | Yes |
| Event | 62nd International Congress of the European Society for Cardiovascular and Endovascular Surgery - Regensburg, Germany Duration: 11 Apr 2013 → 13 Apr 2013 Conference number: 62 https://www.researchgate.net/publication/332404171_62_kongres_European_Society_for_Cardiovascular_and_Endovascular_Surgery_2013_v_Rezne |
Field of Science*
- 3.2 Clinical medicine
Publication Type*
- 3.4. Other publications in conference proceedings (including local)